2020
Imaging Appearance of Nongerminoma Pediatric Ovarian Germ Cell Tumors Does Not Discriminate Benign from Malignant Histology
Billmire D, Dicken B, Rescorla F, Ross J, Piao J, Huang L, Krailo M, Pashankar F, Frazier L, Group C. Imaging Appearance of Nongerminoma Pediatric Ovarian Germ Cell Tumors Does Not Discriminate Benign from Malignant Histology. Journal Of Pediatric And Adolescent Gynecology 2020, 34: 383-386. PMID: 33316416, PMCID: PMC8096645, DOI: 10.1016/j.jpag.2020.11.014.Peer-Reviewed Original ResearchConceptsMalignant ovarian germ cell tumorsMalignant germ cell tumorsGerm cell tumorsOvarian germ cell tumorsCell tumorsOncology GroupMalignant histologyImaging appearancesExtracranial malignant germ cell tumorsNonseminomatous malignant germ cell tumorsOvarian malignant germ cell tumorsSolid appearanceComplete surgical stagingElement of teratomaPediatric ovarian neoplasmsPreoperative serum markersChildren's Oncology GroupPrimary ovarian tumorsYolk sac tumorYears of ageAssociated teratomaTeratoma elementsSurgical stagingMixed histologyMulticenter trial
2019
α‐Fetoprotein as a predictor of outcome for children with germ cell tumors: A report from the Malignant Germ Cell International Consortium
O’Neill A, Xia C, Krailo MD, Shaikh F, Pashankar FD, Billmire DF, Olson TA, Amatruda JF, Villaluna D, Huang L, Malogolowkin M, Rodriguez‐Galindo C, Frazier AL. α‐Fetoprotein as a predictor of outcome for children with germ cell tumors: A report from the Malignant Germ Cell International Consortium. Cancer 2019, 125: 3649-3656. PMID: 31355926, DOI: 10.1002/cncr.32363.Peer-Reviewed Original ResearchConceptsGerm cell tumorsChildren's Oncology GroupCell tumorsAFP declineCumulative incidenceOncology GroupOverall survivalPediatric patientsThree-year overall survivalFuture clinical trial designTumor marker declineStart of chemotherapyPredictors of outcomeRecognition of patientsClinical trial designYears of ageAdult patientsPoor prognosisSerum AFPMarker declineStratified analysisHigh riskTrial designPatientsEarly intensificationAlfa-feto protein (AFP) as a predictor of outcome for children with germ cell tumors: A report from the malignant germ cell international consortium.
O'Neill A, Xia C, Krailo M, Shaikh F, Pashankar F, Billmire D, Olson T, Amatruda J, Villaluna D, Malogolowkin M, Rodriguez-Galindo C, Frazier A. Alfa-feto protein (AFP) as a predictor of outcome for children with germ cell tumors: A report from the malignant germ cell international consortium. Journal Of Clinical Oncology 2019, 37: 10036-10036. DOI: 10.1200/jco.2019.37.15_suppl.10036.Peer-Reviewed Original ResearchEvent-free survivalGerm cell tumorsAFP declinePediatric patientsCell tumorsTumor marker declineStart of chemotherapyDays of chemotherapyStandard-risk diseaseYears of ageAdult patientsRisk diseasePoor prognosisSerum AFPMarker declineStratified analysisPatientsChemotherapyTumorsInitial daysDaysDeclinePrognosisDisease
2013
Weight Status of Children With Sickle Cell Disease
Chawla A, Sprinz PG, Welch J, Heeney M, Usmani N, Pashankar F, Kavanagh P. Weight Status of Children With Sickle Cell Disease. Pediatrics 2013, 131: e1168-e1173. PMID: 23460681, DOI: 10.1542/peds.2012-2225.Peer-Reviewed Original ResearchConceptsSickle cell diseaseBaseline Hb levelsHb levelsBMI percentileWeight statusCell diseaseHigher baseline Hb levelsSCD-related complicationsRetrospective chart reviewObesity-related conditionsOverweight/obesityRecent clinic visitYears of ageCalendar year 2007Select comorbiditiesChart reviewClinic visitsDL increaseElevated BMIHemoglobin levelsObese statusSickle genotypeUnderweight individualsHb SSDemographic information
2012
Development of a Therapeutic Approach to Rare Cancers in Children
Pashankar FD, Rodriguez-Galindo C, Pappo A. Development of a Therapeutic Approach to Rare Cancers in Children. Journal Of Pediatric Hematology/Oncology 2012, 34: s37-s38. PMID: 22525404, DOI: 10.1097/mph.0b013e31824e378e.Peer-Reviewed Original Research
2010
Understanding Provider Barriers to Hydroxyurea Use for Pediatric Sickle Cell Disease
Oyeku S, Green N, Pashankar F, Giardina P, Mullen C, Driscoll C. Understanding Provider Barriers to Hydroxyurea Use for Pediatric Sickle Cell Disease. Blood 2010, 116: 255. DOI: 10.1182/blood.v116.21.255.255.Peer-Reviewed Original ResearchSickle cell diseaseYears of ageEfficacy of hydroxyureaHU useUse of hydroxyureaMajority of providersCell diseaseSickle cell genotypeProvider barriersClinical indicationsHematology providersNIH Consensus Development ConferencePediatric sickle cell diseaseLong-term side effectsNational evidence-based guidelinesProvider levelBroader clinical indicationsChronic pain useAcute chest syndromePhase III trialsPatients ages 1Dose of hydroxyureaEvidence-based guidelinesOff-label useConsensus Development Conference